当前位置: 首页 > 期刊 > 《中国医药导报》 > 2020年第4期
编号:1355673
胃癌腹膜转移治疗的研究进展
http://www.100md.com 2020年4月3日 中国医药导报 2020年第4期
     韩博涵 吕慧芳 陈小兵

    [摘要] 胃癌腹膜转移发病率高,生存期短,是晚期胃癌死亡的主要原因之一。尽管胃癌腹膜转移的诊疗措施在不断进步,但胃癌腹膜转移患者的预后仍较差。有效预防胃癌腹膜转移的发生与胃癌腹膜转移的治疗同等重要。腹膜转移高危人群给予预防性腹腔热灌注化疗、术中腹腔灌注化疗、术后早期腹腔化疗及术后辅助化疗,可改善患者的预后。胃癌腹膜转移的治疗以全身化疗为主,可联合多种治疗手段,包括腹腔灌注化疗、靶向治疗及免疫治疗等,特别是转化治疗可明显改善胃癌腹膜转移患者的预后,但转化治疗人群的选择、方案的选择及转化的时机仍是目前的重点和难点。本文将对近年来胃癌腹膜转移治疗的研究现状进行概述,从而为临床实践提供一定的参考。

    [关键词] 胃癌;腹膜转移;预防;治疗

    [中图分类号] R735.2? ? ? ? ? [文献标识码] A? ? ? ? ? [文章编号] 1673-7210(2020)02(a)-0028-05

    [Abstract] Peritoneal metastasis of gastric cancer has high incidence and short survival time, which is one of the main causes of death in advanced gastric cancer. In spite of several advances have been made in diagnosis and treatment, the prognosis of patients with peritoneal metastasis is still lower. Effective preventive measures are as important as treatment of peritoneal metastasis. Hyperthemic intraperitoneal perfusion chemotherapy, extensive intraoperative peritoneal lavage, early postoperative intraperitoneal chemotherapy and postoperative adjuvant chemotherapy can improve the prognosis of patients with peritoneal metastasis in high-risk groups. The systemic chemotherapy is the main treatment for peritoneal metastasis of gastric cancer ......

您现在查看是摘要页,全文长 16013 字符